Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight Average endpoint/change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain
It is very uncertain whether metformin changes leaving the study early: for any reason compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Nausea · people with schizophrenia with antipsychotic‐induced weight gain
Metformin showed no clear difference in reports of nausea compared with placebo or no treatment (low certainty).
1 finding from 1 review
Hypertensive disorders of pregnancy · women with gestational diabetes mellitus
Metformin showed no clear difference in hypertensive disorders of pregnancy compared with glibenclamide ‐ maternal outcomes (moderate certainty).
1 finding from 1 review
Caesarean section · women with gestational diabetes mellitus
Metformin showed no clear difference in caesarean section compared with glibenclamide ‐ maternal outcomes (low certainty).
1 finding from 1 review
Development of type 2 diabetes ‐ not measured · women with gestational diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Perineal trauma · women with gestational diabetes mellitus
Metformin showed no clear difference in perineal trauma compared with glibenclamide ‐ maternal outcomes (low certainty).
1 finding from 1 review
Return to pre‐pregnancy weight ‐ not measured · women with gestational diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Postnatal depression ‐ not measured · women with gestational diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Induction of labour · women with gestational diabetes mellitus
Metformin showed no clear difference in induction of labour compared with glibenclamide ‐ maternal outcomes (low certainty).
1 finding from 1 review
Large‐for‐gestational age · Infants of women diagnosed with gestational diabetes
Metformin showed no clear difference in large‐for‐gestational age compared with glibenclamide ‐ neonatal outcomes (low certainty).
1 finding from 1 review
Perinatal mortality · Infants of women diagnosed with gestational diabetes
It is very uncertain whether metformin changes perinatal mortality compared with glibenclamide ‐ neonatal outcomes (very low certainty).
1 finding from 1 review
Death or serious morbidity composite · Infants of women diagnosed with gestational diabetes
Metformin may leads to lower death or serious morbidity composite compared with glibenclamide ‐ neonatal outcomes (low certainty).
1 finding from 1 review
Neonatal hypoglycaemia · Infants of women diagnosed with gestational diabetes
Metformin showed no clear difference in neonatal hypoglycaemia compared with glibenclamide ‐ neonatal outcomes (low certainty).
1 finding from 1 review
Adiposity ‐ not reported · Infants of women diagnosed with gestational diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Diabetes ‐ not measured · Infants of women diagnosed with gestational diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found